Astellas
Astellas Pharma UK is the British subsidiary of the Japanese pharmaceutical company Astellas, developing innovative medicines in urology, oncology, and transplantation. Key products include XTANDI (enzalutamide) for metastatic and non-metastatic castration-resistant prostate cancer, Prograf and Advagraf (tacrolimus) for transplant rejection prevention in kidney, liver, and heart transplant patients, and Betmiga (mirabegron) for overactive bladder syndrome. Medical Information: 0800 783 5018.
How to Contact Astellas
Phone
+44 (0)20 3379 8700Medical Disclaimer
NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information on this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.
The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.
Experienced a Side Effect?
Report to Yellow Card (UK) or MedWatch (US)
